Retatrutide
Retatrutide (Triple G Receptor Agonist)
Potential Benefits
- Investigational 'triple agonist' targeting GLP-1, GIP, and Glucagon receptors
- Phase 2 trials demonstrated up to 24.2% average body weight reduction in 48 weeks
- Studies indicate profound improvements in cardiovascular biomarkers including blood pressure and lipid profiles
- Research suggests powerful resolution of non-alcoholic fatty liver disease (NAFLD) biomarkers (up to 86% fat clearance in trials)
- Once-weekly injection protocol with potential for dramatic metabolic resets
Recommended Starting Dose
1 mg subcutaneously once weekly (trial titration starting dose)
Based on published research protocols. Not a prescription.
Dosing Protocol
In clinical trials, titration began at 1 mg weekly for 4 weeks (or 2 mg), gradually increasing to 4 mg, 8 mg, and optionally 12 mg weekly based on patient tolerance. Extremely slow and cautious titration is vital to manage gastrointestinal distress and monitor heart rate acceleration. Requires strict clinical oversight.
DOSING INFORMATION DISCLAIMER: Any dosing information, protocols, or ranges discussed on this site are drawn from published research studies and clinical literature. They are presented for educational reference only and must not be used as self-medication guidance.
Expected Timeline
Phase 1
Appetite suppression and initial weight loss typically begin within the first 1-2 weeks. Phase 2 trials showcased rapid and continuous weight loss progressing almost linearly through 48 weeks without signs of early plateauing.
Research Status
The regulatory status of peptides can change at any time. Verify current FDA classification and legal status in your jurisdiction before seeking medical consultation about this compound.
Potential Side Effects
- Nausea and vomiting (dose-dependent; most common during titration phases)
- Diarrhea and constipation
- Temporary increases in resting heart rate (attributed directly to glucagon receptor activation)
- Potential for lean tissue/muscle mass loss if not accompanied by structured resistance training
- Cutaneous hypersensitivity at injection sites
- Long-term safety profile is currently unknown and under evaluation in Phase 3 trials
More in Weight Loss
AOD-9604
Advanced Obesity Drug 9604
AOD-9604 is a modified fragment of human growth hormone (amino acids 177-191) developed by Monash University in Australia. It was designed to retain the fat-reducing properties of GH without the growth-promoting or diabetogenic effects. While initial clinical trials showed promise for obesity, it did not receive FDA approval as a drug.
Tirzepatide
Tirzepatide (Dual GIP/GLP-1 Receptor Agonist)
Tirzepatide is a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist developed by Eli Lilly. It activates both incretin pathways, producing effects on insulin secretion, glucagon suppression, appetite, and body weight. It is FDA-approved for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound).
Medical Disclaimer
EDUCATIONAL CONTENT ONLY: The peptide information presented on this page is compiled from published scientific literature, peer-reviewed research, and publicly available clinical data. It is provided strictly for educational purposes and does not constitute medical advice, an endorsement of any specific peptide, or a recommendation for treatment. Many peptides discussed on this site have not received FDA approval for human therapeutic use. Some may be under active regulatory review or subject to restrictions on compounding under FDA Section 503A and 503B frameworks. The regulatory status of individual peptides can change at any time. Readers should verify the current legal status of any peptide in their jurisdiction before pursuing further information or consultation. If you are considering peptide therapy, seek guidance from a licensed physician or healthcare provider who specializes in peptide-based treatments and operates within applicable federal and state regulations.